Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced the completion of its first export of naturally derived psilocybin to the United Kingdom, supporting a planned Phase 2 clinical trial. The shipment, which includes psilocybin biomass and finished 5 mg psilocybin capsules, was manufactured at the company's GMP facility in Princeton, British Columbia. According to the company, the capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, and the export was authorized by Health Canada and the UK Home Office.
This development underscores Optimi's role as a vertically integrated GMP supplier for both regulated patient access programs and clinical research initiatives. The products were cultivated, extracted, and manufactured in-house under the company's Drug Establishment Licence. Optimi Health is a commercial-stage pharmaceutical company that produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia. The company supplies active pharmaceutical ingredients and finished dosage forms to international clinical and therapeutic programs. Its products are currently prescribed to patients in Australia under the Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program.
The export to the UK is significant as it expands the reach of psychedelic-assisted therapies, potentially offering new treatment options for mental health conditions. The implications for the industry are substantial, as it demonstrates a growing regulatory acceptance of psychedelic compounds for clinical use. This move could pave the way for further international collaborations and clinical trials, accelerating the development of evidence-based treatments. For patients, it represents progress toward accessing innovative therapies for conditions like treatment-resistant depression. The broader impact on the world includes advancing the understanding of psychedelics in mental health care and potentially reducing the stigma associated with these substances.
For more information, visit https://ibn.fm/WLDHZ for the full press release. Optimi Health Corp. is listed on NASDAQ as OPTH, on the CSE as OPTI, and on the FSE as 8BN. The company's facilities are located in British Columbia, Canada, and it is licensed by Health Canada as a pharmaceutical manufacturer. Optimi Health's focus on GMP-grade psychedelic drug products positions it as a key player in the emerging field of psychedelic medicine.
